
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list. What prompted the FDA to reconsider its decision? On Oct. 7, a compounding trade group filed a lawsuit challenging the agency’s action, saying there was still a shortage of the wildly popular drug. On Friday, the FDA responded in a court filing that compounding pharmacies could continue making the drug while the agency re-evaluates its finding, NBC News reported. Shortages of tirzepatide, sold as a diabetes drug (Mounjaro) and a weight-loss medication (Zepbound), have fueled demand for compounding pharmacies to make their own versions of the medicine, which patients say are cheaper and easier to get. During FDA-declared drug shortages, compounding pharmacies can make versions that are copies of the brand-name drugs in shortage. But the agency’s Oct. 2 announcement said pharmacies that produce large batches of medications would no longer be able to accept new orders of tirzepatide and had 60 days to fill their existing orders. The agency’s Friday filing said its latest move was “effectively the relief that Plaintiffs sought in their motion.” In the filing, the agency said it wouldn’t “take action” against the plaintiffs and their members making compounded versions of the drugs as it re-evaluates its decision, NBC News reported. … read on > read on >